Immunotherapy Using Donor Cells Safe in PML Immunotherapy Using Donor Cells Safe in PML

Pilot results in a small number of patients with PML suggests safety of an approach using adoptive cellular immunotherapy generated from cells taken from a healthy related donor.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Related Links:

Publication date: Available online 19 June 2019Source: The Journal of Steroid Biochemistry and Molecular BiologyAuthor(s): Diana C. Márquez-Garbán, Gang Deng, Begonya Comin-Anduix, Alejandro J. Garcia, Yanpeng Xing, Hsiao-Wang Chen, Gardenia Cheung-Lau, Nalo Hamilton, Michael E. Jung, Richard J. PietrasAbstractBreast cancers (BC) with expression of estrogen receptor-alpha (ERα) occur in more than 70% of newly-diagnosed patients in the U.S. Endocrine therapy with antiestrogens or aromatase inhibitors is an important intervention for BCs that express ERα, and it remains one of the most effective tar...
Source: The Journal of Steroid Biochemistry and Molecular Biology - Category: Biochemistry Source Type: research
Authors: De Goycoechea D, Stalder G, Martins F, Duchosal MA Abstract Immune checkpoint inhibition (ICI) became one of the major breakthroughs in cancer treatment over the past decade and entered into therapy within standard oncohematology practice. ICI has demonstrated impressive response rates as salvage therapy in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) and is now being tested as an adjunction to chemotherapy in the frontline settings. CHL exquisite sensitivity to PD-1/PD-L1 axis inhibition relies on a particular biological background. By contrast, non-Hodgkin lymphomas (NHL) have demonstrated ...
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
Authors: Oba R, Isomura M, Igarashi A, Nagata K Abstract Extracellular vesicles (EVs) are known to contain unique proteins that reflect the cells of origins. Activated T cells are reported to secrete various EVs. To establish T cell subset-specific biomarkers, we performed proteomic analysis with Th1- and Th2-derived EVs and identified HLA-DR as a Th1-dominated EV membrane protein. We designed a measurement system for CD3+CD4+, CD3+CD8+, and CD3+HLA-DR+ EVs to specifically determine EV subpopulations derived from CD4+, CD8+, and Th1-type T cells, respectively. In vitro analysis showed that CD3+CD4+ EVs and CD3+CD8+...
Source: Journal of Immunology Research - Category: Allergy & Immunology Tags: J Immunol Res Source Type: research
Conditions:   Solid Tumor;   Lymphoma Interventions:   Drug: Manganese Chloride;   Drug: Anti-PD-1 antibody;   Combination Product: Systemic therapy Sponsor:   Chinese PLA General Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Alemtuzumab and abatacept were both successfully used in patients with steroid-refractory myocarditis that developed during treatment with immune checkpoint inhibitors.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Conclusion: Despite the considerably high rate of VIT-ISR in patients with exclusive BV allergy, VIT can be performed safely and efficiently. C-kit mutation, and not basal serum tryptase level, seems to be a preferable biomarker for VIT-ISR in these patients.Int Arch Allergy Immunol
Source: International Archives of Allergy and Immunology - Category: Allergy & Immunology Source Type: research
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
In this report, we present a case of pembrolizumab-induced autoimmune hemolytic anemia and pancytopenia in a patient who was receiving pembrolizumab treatment for metastatic melanoma. This patient has a history of chronic lymphocytic leukemia and was diagnosed with metastatic melanoma in 2017. He developed symptomatic AIHA and pancytopenia after receiving 8 cycles of pembrolizumab in 2018. Pembrolizumab treatment was discontinued and he was treated with blood transfusion and prednisone. After 5 months of tapering prednisone treatment, his anemia and pancytopenia have improved toward successful recovery. Cancer patients alr...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
Recent clinical trials have put immunotherapy front and center for initial treatment decisions in advanced lung cancer.Journal of Clinical Oncology
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Hematology-Oncology Journal Article Source Type: news
Cancer Network spoke with Paul B. Chapman, MD, of Memorial Sloan Kettering Cancer Center, about pursuing adjuvant immunotherapy for patients with melanoma.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
More News: Brain | Immunotherapy | Neurology | Neurosurgery